IHE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IH

Volume

457.79K

Loading chart

IH

IHEiShares U.S. Pharmaceuticals ETF

IHE

Pay with—

Available Balance0.00

IH

AUM

N/A

Volume

457.79K

Yield

1.10%

Chart Earnings News About Dividends Insider Filings

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios.Zacks Investment Research · Oct 15, 2026

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?The State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed fund offering broad exposure to the pharmaceutical sector with low costs (0.35% expense ratio) and solid year-to-date performance of 12.61%. However, the Healthcare-Pharma sector ranks 11th out of 16 Zacks sectors, and the ETF carries a 'Hold' rating with high risk (beta of 0.61, standard deviation of 20.68%). Investors may also consider alternative pharma ETFs like FTXH and IHE.Zacks Investment Research · Oct 8, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.Zacks Investment Research · Oct 5, 2026

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund offering broad exposure to the Healthcare-Pharma sector with $1.63 billion in assets. The ETF has delivered strong year-to-date returns of 20.69% and 45.67% over the past year, though it carries higher risk with a beta of 0.49 and standard deviation of 16.8%. It holds approximately 60 pharmaceutical companies with top holdings including Johnson & Johnson (22.21%), Eli Lilly, and Bristol Myers Squibb, and carries a Zacks ETF Rank of 3 (Hold).Zacks Investment Research · Sep 15, 2026

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.The Motley Fool · Sep 8, 2026

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) offer different approaches to healthcare investing. FHLC provides broad diversification across 338 healthcare holdings with a lower 0.08% expense ratio, while IHE focuses on 56 pharmaceutical stocks with higher concentration risk but delivered 60% one-year returns. The analysis recommends FHLC for its superior diversification and lower costs, despite IHE's recent outperformance.The Motley Fool · Aug 14, 2026

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.The Motley Fool · Jul 22, 2026

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.The Motley Fool · Jul 19, 2026

iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF ReturnsThe iShares U.S. Pharmaceuticals ETF (IHE) outperformed the Simplify Health Care ETF (PINK) over the past year, delivering 42.40% returns versus 29.30%. IHE offers lower costs (0.38% expense ratio), higher dividend yield (1.62%), and focuses on established pharmaceutical giants like Eli Lilly and Johnson & Johnson. While PINK provides active management with innovation focus and donates profits to breast cancer research, its higher expense ratio (0.51%) and recent underperformance give IHE the edge for 2026.The Motley Fool · Jun 10, 2026

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.IHE (U.S. Pharmaceuticals ETF) significantly outperformed IXJ (Global Healthcare ETF) over the past year, driven largely by GLP-1 drug success, particularly from Eli Lilly. While IHE's concentrated focus on domestic pharma delivered 39.70% returns, IXJ's broader global healthcare approach provided more diversification but only 10% returns. Both funds charge similar fees, making the choice dependent on investor preference for concentration versus diversification.The Motley Fool · May 27, 2026

to start trading

IH

IHEiShares U.S. Pharmaceuticals ETF

IHE

Pay with—

Available Balance0.00

Your PositionYou don't own any IHE yet.

Related Tickers

Earnings

Dividends

Last · Sep 15Quarterly

Amount$0.28

Yield1.42%

Annual$1.43